These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22624727)

  • 21. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
    Rancea M; Will A; Borchmann P; Monsef I; Engert A; Skoetz N
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25031306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
    Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
    Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
    Rigacci L; Puccini B; Cortelazzo S; Gaidano G; Piccin A; D'Arco A; Freilone R; Storti S; Orciuolo E; Zinzani PL; Zaja F; Bongarzoni V; Balzarotti M; Rota-Scalabrini D; Patti C; Gobbi M; Carpaneto A; Liberati AM; Bosi A; Iannitto E
    Ann Hematol; 2012 Jul; 91(7):1013-22. PubMed ID: 22349722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
    Klasa RJ
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
    Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC; Blum KA
    Blood; 2015 Jan; 125(2):242-8. PubMed ID: 25355819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
    Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW
    Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo (1)H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP.
    Lee SC; Delikatny EJ; Poptani H; Pickup S; Glickson JD
    NMR Biomed; 2009 Apr; 22(3):259-65. PubMed ID: 19040203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
    de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
    Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
    Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
    Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
    [No Abstract]   [Full Text] [Related]  

  • 33. Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
    Waldthaler C; Stauder R; Schnallinger M; Schreieck S; Hager J; Oexle H; Zangerl G; Verdorfer I; Zabernigg A; Gastl G; Fiegl M
    Wien Klin Wochenschr; 2011 May; 123(9-10):269-75. PubMed ID: 21479652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
    Rummel MJ
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
    Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
    J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.
    Weidmann E; Neumann A; Fauth F; Atmaca A; Al-Batran SE; Pauligk C; Jäger E
    Ann Oncol; 2011 Aug; 22(8):1839-44. PubMed ID: 21257672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
    Kipps TJ; Eradat H; Grosicki S; Catalano J; Cosolo W; Dyagil IS; Yalamanchili S; Chai A; Sahasranaman S; Punnoose E; Hurst D; Pylypenko H
    Leuk Lymphoma; 2015; 56(10):2826-33. PubMed ID: 25797560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
    J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.